High purity Retatrutide raw peptide powder 2mg/5mg/10mg/15mg Used for weight loss

Glutathione

Glycine,L-γ-glutamyl-L-cysteinyl-;Glutathione;Glycine,N-(N-L-γ-glutamyl-L-cysteinyl)-;L-γ-Glutamyl-L-cysteinylglycine;γ-L-Glutamyl-L-cysteinylglycine;Glutathione-SH;GSH;L-Glutathione;Reduced glutathione;Triptide;Glutide;Tathion;Tathione;Copren;Deltathione;Glutathion;Glutinal;Isethion;Neuthion;Agifutol S;γ-Glutamylcysteinylglycine;N-(N-L-γ-Glutamyl-L-cysteinyl)glycine;Bakezyme RX;ReadiSorb;Atomolan;High Thione Extract YH 15;N5-((R)-1-((Carboxymethyl)amino)-3-mercapto-1-oxopropan-2-yl)-L-glutamine;TAD 600;1109226-07-4;1655518-50-5

70-18-8

C10H17N3O6S

InChIKey=RWSXRVCMGQZWBV-WDSKDSINSA-N

307.32300

307.32

200-725-4

GAN16C9B8O

758199

DTXSID6023101

C523

V - Various

2930909090

Bulk Drug Intermediates

197.62000

-4.5

Solid

1.441 g/cm3

195 °C

410.1ºC

410.1±32.9 °C

1.571

H2O: 292.5 mg/mL

2-8ºC

167.4 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with Agilent tune mix (Agilent)]|168.23 Ų [M+Na]+ [CCS Type: DT, Method: stepped-field]|164.24 Ų [M-H]- [CCS Type: DT, Method: stepped-field]|165 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine]|167.8 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|167 Ų [M+Na]+ [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|162.1 Ų [M-H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|164.8 Ų [M+Na-2H]- [CCS Type: DT, Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]|165.7 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]|164.8 Ų [M-2H+Na]-

Triple agonist — GCGR, GIPR, GLP-1R

Investigational (Phase 3)

Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

5.79 nM

0.191 nM

0.794 nM

2.32 nM

0.775 nM

0.0643 nM

Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

NCT04881760; NCT05882045; NCT06354660

CHEMBL5095485

DB18993

D12430

PubChem

NEJM: Jastreboff et al. (2023) — Phase 2 Trial; FDA Drugs@FDA

Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.